Pfizer has licensed non-exclusive, worldwide rights to Xoma Ltd.’s bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products. Under the terms of the agreement, Xoma will receive an upfront cash payment of $30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development. Steven Engle, chief executive off...